Skip to main contentSkip to navigation
Sirius Investors
Basilea Pharmaceutica AG

Basilea Pharmaceutica AG

BPMUF
OTCHealthcare

Basilea Pharmaceutica AG (BPMUF) Investment Research Dashboard

About Basilea Pharmaceutica AG (BPMUF) stock analysis

Get live BPMUF stock price $60.27, comprehensive Basilea Pharmaceutica AG stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time BPMUF stock data and investment insights.

60.27
0.00%Today
Market Cap
746.00M
Volume
0
52W High
74.00
52W Low
47.50

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Basilea Pharmaceutica AG is a biopharmaceutical company already generating revenue from its products, which are designed to fulfill medical needs in the challenging areas of cancer (oncology) and infectious diseases (anti-infectives). The company's p...

Company Information

CEO
David Veitch
Sector
Healthcare
Industry
Biotechnology
Employees
189

Contact Information

Address
Hegenheimermattweg 167b
Country
CH

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Valuation metrics suggest potential value opportunity (P/E: 8.5)

Lower volatility stock (Beta: 0.42) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Basilea Pharmaceutica AG shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Basilea Pharmaceutica AG
  • Investors should consider how Basilea Pharmaceutica AG fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

746.00M

P/E Ratio (TTM)

8.47

Beta

0.42

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

78/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+3.1%+4.3%19.3
98/100⭐⭐⭐⭐⭐
Healthcare+0.7%+1.3%+1.6%24.1
78/100⭐⭐⭐⭐⭐
Communication Services+1.4%-0.7%+2.9%22.2
74/100⭐⭐⭐⭐⭐
Consumer Defensive-0.2%+1.8%+0.7%29.7
64/100⭐⭐⭐⭐
Basic Materials+0.4%+1.2%-0.2%25.2
61/100⭐⭐⭐⭐
Real Estate-0.5%+0.0%-2.5%29.2
43/100⭐⭐⭐
Energy-2.1%-3.7%-4.1%19.1
39/100⭐⭐
Utilities-1.0%+0.0%-4.4%26.8
37/100⭐⭐
Industrials+0.6%+0.4%-9.9%30.1
23/100
Consumer Cyclical+0.5%-1.5%-5.8%43.0
18/100
Technology+0.6%-1.6%-7.2%40.7
15/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.